<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        72-116-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MEGION 1GM I.V - I.M INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTRIAXONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        g
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="SANDOZ" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Megion&reg; is an antibiotic given to adults and children (including newborn babies). It works by killing bacteria that cause infections. It belongs to a group of medicines called cephalosporins<em>.</em></p><p><em>&nbsp;</em></p><p>Megion&reg; is used to treat infections of</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the brain (meningitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the lungs.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the middle ear.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the abdomen and abdominal wall (peritonitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the urinary tract and kidneys.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bones and joints.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the skin or soft tissues.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the blood.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the heart.</p><p>&nbsp;</p><p>It can be given:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat specific sexually transmitted infections (gonorrhoea and syphilis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat patients with low white blood cell counts (neutropenia) who have fever due to bacterial infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat infections of the chest in adults with chronic bronchitis.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat Lyme disease (caused by tick bites) in adults and children including newborn babies from 15 days of age.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to prevent infections during surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You must not be given Megion&reg; if:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to ceftriaxone or any of the other ingredients of this medicine (listed in section 6).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have had a sudden or severe allergic reaction to penicillin or similar antibiotics (such as cephalosporins, carbapenems or monobactams). The signs include sudden swelling of the throat or face which might make it difficult to breath or swallow, sudden swelling of the hands, feet and ankles, and a severe rash that develops quickly.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are allergic to lidocaine and you are to be given Megion&reg; as an injection into a muscle.</p><p>&nbsp;</p><p><strong>Megion&reg; must not be given to babies if:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baby is premature.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The baby is newborn (up to 28 days of age) and has certain blood problems or jaundice (yellowing of the skin or the whites of the eyes) or is to be given a product that contains calcium into their vein.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist or nurse before you are given Megion&reg; if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently received or are about to receive products that contain calcium.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have recently had diarrhoea after having an antibiotic medicine. You have ever had problems with your gut, in particular colitis (inflammation of the bowel).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have liver or kidney problems (see section 4).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have gall stones or kidney stones</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have other illnesses, such as haemolytic anaemia (a reduction in your red blood cells that may make your skin pale yellow and cause weakness or breathlessness).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are on a low sodium diet.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; You experience or have previously experienced a combination of any of the following symptoms: rash, red skin, blistering of the lips eyes and mouth, skin peeling, high fever, flu- like symptoms, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (signs of severe skin reactions, see also section 4 &ldquo;Possible side effects&rdquo;).</p><p>&nbsp;</p><p><strong>If you need a blood or urine test</strong></p><p>If you are given Megion&reg; for a long time, you may need to have regular blood tests. Megion&reg; can affect the results of urine tests for sugar and a blood test known as the Coombs test. If you are having tests:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tell the person taking the sample that you have been given Megion&reg; .</p><p>If you are diabetic or need to have your blood glucose level monitored you should not use certain blood glucose monitoring systems which may estimate blood glucose incorrectly while you are receiving ceftriaxone. If you use such systems check the instructions for use and tell your doctor, pharmacist or nurse. Alternative testing methods should be used if necessary.</p><p>&nbsp;</p><p><strong>Children</strong></p><p>Talk to your doctor or pharmacist or nurse before your child is administered Megion&reg; if:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; He/She has recently been given or is to be given a product that contains calcium into their vein.</p><p><strong>Other medicines and Megion&reg;</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A type of antibiotic called an aminoglycoside.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An antibiotic called chloramphenicol (used to treat infections, particularly of the eyes).</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p>The doctor will consider the benefit of treating you with Megion&reg; against the risk to your baby.</p><p><strong>Driving and using machines</strong></p><p>Megion&reg; can cause dizziness. If you feel dizzy, do not drive or use any tools or machines. Talk to your doctor if you experience these symptoms.</p><p>&nbsp;</p><p><strong>Megion&reg; contains sodium</strong></p><p><strong>&nbsp;</strong></p><p><em>0.5 g powder for solution for injection:</em></p><p>This medicine contains 42 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 2.1% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p><em>1 g powder for solution for injection:</em></p><p>This medicine contains 83 mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 4.2% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Megion&reg; is usually given by a doctor or nurse. It can be given as a drip (intravenous infusion) or as an injection directly into a vein or into a muscle. Megion&reg; is made up by the doctor, pharmacist or nurse and will not be mixed with or given to you at the same time as calcium-containing injections.</p><p>&nbsp;</p><p><strong>The usual dose</strong></p><p><strong>&nbsp;</strong>Your doctor will decide the correct dose of Megion&reg; for you. The dose will depend on the severity and type of infection; whether you are on any other antibiotics; your weight and age; how well your kidneys and liver are working. The number of days or weeks that you are given Megion&reg; depends on what sort of infection you have.</p><p>&nbsp;</p><p><strong>Adults, older people and children aged 12 years and over with a body weight greater than or equal to 50 kilograms (kg):</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 to 2 g once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose (up to 4 g once a day). If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p><strong>Newborn babies, infants and children aged 15 days to 12 years with a body weight of less than 50 kg:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50-80 mg Megion&reg; for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection. If you have a severe infection, your doctor will give you a higher dose up to 100 mg for each kg of body weight to a maximum of 4 g once a day. If your daily dose is higher than 2 g, you may receive it as a single dose once a day or as two separate doses.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children with a body weight of 50 kg or more should be given the usual adult dose.</p><p>&nbsp;</p><p><strong>Newborn babies (0-14 days)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 &ndash; 50 mg Megion&reg; for each kg of the child&rsquo;s body weight once a day depending on the severity and type of infection.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The maximum daily dose is not to be more than 50 mg for each kg of the baby&rsquo;s weight.</p><p>&nbsp;</p><p><strong>People with liver and kidney problems</strong></p><p>You may be given a different dose to the usual dose. Your doctor will decide how much Megion&reg; you will need and will check you closely depending on the severity of the liver and kidney disease.</p><p>&nbsp;</p><p><strong>If you are given more Megion&reg; than you should</strong></p><p>If you accidentally receive more than your prescribed dose, contact your doctor or nearest hospital straight away.</p><p>&nbsp;</p><p><strong>If you forget to use Megion&reg;</strong></p><p>If you miss an injection, you should have it as soon as possible. However, if it is almost time for your next injection, skip the missed injection. Do not take a double dose (two injections at the same time) to</p><p>make up for a missed dose.</p><p>&nbsp;</p><p><strong>If you stop using Megion&reg;</strong></p><p>Do not stop taking Megion&reg; unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>&nbsp;</p><p><strong>Severe allergic reactions (not known, frequency cannot be estimated from the available data)</strong></p><p>If you have a severe allergic reaction, tell a doctor straight away. The signs may include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the face, throat, lips or mouth. This can make it difficult to breathe or swallow.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of the hands, feet and ankles.</p><p>&nbsp;</p><p><strong>Severe skin reactions (not known, frequency cannot be estimated from the available data)</strong></p><p>If you get a severe skin reaction, tell a doctor straight away. The signs may include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A severe rash that develops quickly, with blisters or peeling of the skin and possibly blisters in the mouth (Stevens-Johnson syndrome and toxic epidermal necrolysis which are also known as SJS and TEN).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; A combination of any of the following symptoms: widespread rash, high body temperature, liver enzyme elevations, blood abnormalities (eosinophilia), enlarged lymph nodes and other body organs involvement (Drug Reaction with Eosinophilia and Systemic Symptoms which is also known as DRESS or drug hypersensitivity syndrome).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp; Jarisch-Herxheimer reaction which causes fever, chills, headache, muscle pain, and skin rash that is usually self-limiting. This occurs shortly after starting cetriaxone treatment for infections with spirochete such as Lyme disease.</p><p>&nbsp;</p><p>Other possible side effects:</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormalities with your white blood cells (such as a decrease of leucocytes and an increase of eosinophils) and platelets (decrease of thrombocytes).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loose stools or diarrhoea.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in the results of blood tests for liver functions.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash.</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infections (for example, thrush).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A decrease in the number of white blood cells (granulocytopenia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in number of red blood cells (anaemia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with the way your blood clots. The signs may include bruising easily and pain and swelling of your joints.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling sick or being sick.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pruritis (itching).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or a burning feeling along the vein where Megion&reg; has been given. Pain where the injection was given.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A high temperature (fever).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal kidney function test (blood creatinine increased).</p><p>&nbsp;</p><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the large bowel (colon). The signs include diarrhoea, usually with blood and mucus, stomach pain and fever.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing (bronchospasm).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A lumpy rash (hives) that may cover a lot of your body, feeling itchy and swelling.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood or sugar in your urine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (fluid build-up).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shivering.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with ceftriaxone, particularly in elderly patients with serious kidney or nervous system problems may rarely cause decreased consciousness, abnormal movements, agitation and convulsions.</p><p><strong>Not known (Frequency cannot be estimated from the available data)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A secondary infection that may not respond to the antibiotic previously prescribed</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form of anaemia where red blood cells are destroyed (haemolytic anaemia).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe decrease in white blood cells (agranulocytosis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Convulsions.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vertigo (spinning sensation).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas (pancreatitis). The signs include severe pain in the stomach which spreads to your back.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the mucus lining of the mouth (stomatitis).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the tongue (glossitis). The signs include swelling, redness and soreness of the tongue.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your gallbladder and/or liver, which may cause pain, nausea, vomiting, yellowing of the skin, itching, unusually dark urine and clay-coloured stools.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A neurological condition that may occur in neonates with severe jaundice (kernicterus).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kidney problems caused by deposits of calcium ceftriaxone. There may be pain when passing water (urine) or low output of urine.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive result in a Coombs&rsquo; test (a test for some blood problems).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A false positive result for galactosaemia (an abnormal build up of the sugar galactose).</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Megion&reg; may interfere with some types of blood glucose tests - please check with your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Reconstituted solution:</p><p>Once the powder has been dissolved; the solution should be used immediately or stored in a refrigerator at 2-8&deg;C and discarded after 48 hours.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Megion&reg; 0.5 g powder and solvent for solution for injection:</p><p>Powder: The active substance is ceftriaxone</p><p>Each vial contains: 0.5 g ceftriaxone (as ceftriaxone disodium, hydrated)</p><p>Each lidocaine hydrochloride ampoule contains: 1% (20 mg/2 ml) lidocaine hydrochloride, water for injection, sodium hydrogen carbonate</p><p>&nbsp;</p><p>Megion&reg; 1 g powder and solvent for solution for injection:</p><p>Powder: The active substance is ceftriaxone</p><p>Each vial contains: 1 g ceftriaxone (as ceftriaxone disodium, hydrated)</p><p>Each lidocaine hydrochloride ampoule contains: 1% (35 mg/3.5 ml) lidocaine hydrochloride, water for injection, sodium hydrogen carbonate</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Powder and solvent for solution for injection/infusion.

The powder is coloured white to yellowish. The solvent is a clear and colourless solution.


Pack sizes:
1 vial + 1 ampoule

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;&nbsp;&nbsp;&nbsp; Sandoz GmbH, Kundl, Austria</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">عقار ميجيون<sup>&reg;</sup> هو أحد المضادات الحيوية التي يتم إعطاؤها للبالغين والأطفال (بما في ذلك حديثو الولادة). يعمل العقار من خلال القضاء على البكتيريا التي تُسبب العدوى. وينتمي إلى مجموعة من الأدوية تسمى السيفالوسبورينات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار ميجيون<sup>&reg;</sup> لعلاج العدوى التي تصيب الآتي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المخ (الْتِهاب السّحَايَا).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرئتين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأذن الوسطى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البطن وجدار البطن (الْتِهاب الصِّفاق).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المسالك البولية والكُلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العظام والمفاصل.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجلد أو الأنسجة الرَّخوة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدَّم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاؤه في الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج عدوى محددة تنتقل جنسيًّا (السَّيَلَان ومرض الزهري).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج المرضى الذين يعانون من انخفاض تعدادات خلايا الدَّم البيضاء (قلة خلايا العَدِلات) المُصابين بحُمى ناجمة عن عدوى بكتيرية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج عدوى الصدر في البالغين المُصابين بالتهاب الشعب الهوائية المزمن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لعلاج مرض لايم (النَّاجم عن لدغات القراد) في البالغين والأطفال بما في ذلك حديثو الولادة بدءًا من عمر 15 يومًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للوقاية من العدوى أثناء الخضوع للجراحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب ألا يتم إعطاؤك عقار ميجيون<sup>&reg;</sup> في الحالات الآتية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه سيفترياكسون أو تجاه أيِّ مكون من المكونات الأخرى الموجودة بهذا الدَّواء (المدرجة في قسم 6).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أُصبت بتفاعل حساسية مفاجئ أو شديد تجاه البنسيلين أو المضادات الحيوية المشابهة (مثل: السيفالوسبورينات، الكاربابينيمات أو المضادات الحيوية أُحَادِية الحَلَقَة البيتالاكتاميَّة). تشمل العلامات تورمًا مفاجئًا للحَلْق أو الوجه مما قد يُسبب صعوبة في التَّنفس أو البلع، تورمًا مفاجئًا لليدين والقدمين والكاحلين، وطفحًا جلديًّا شديدًا يتطور سريعًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ليدوكائين ومن المقرر أن يتم إعطاؤك عقار ميجيون<sup>&reg;</sup> على هيئة حَقْن في العضل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يجب عدم إعطاء عقار ميجيون<sup>&reg;</sup> للرُّضَّع في الحالات الآتية:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الرضيع مبتسرًا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان الرضيع حديث الولادة (يصل عمره إلى 28 يومًا) ويعاني من بعض مشاكل الدَّم أو اليرقان (اصفرار الجلد أو بياض العينين) أو من المقرر أن يتم إعطاؤه منتجًا يحتوي على الكالسيوم في الوريد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك قبل أن يتم إعطاؤك عقار ميجيون<sup>&reg;</sup> في الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد تلقيت مؤخرًا أو كنت على وشك تلقي منتجات تحتوي على الكالسيوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت مؤخرًا من الإسهال بعد تناوُل أحد المضادات الحيوية. إذا كنت قد عانيت من قبل من مشاكل في الأمعاء، وخاصة التهاب القولون (التهاب الأمعاء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك مشاكل بالكبد أو الكلى (انظر قسم 4).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حصوات في المرارة أو حصوات في الكُلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بأمراض أخرى، مثل فقر الدَّم الانحلالي (انخفاض في عدد خلايا الدَّم الحمراء لديك مما قد يتسبب في أن يصبح جلدك أصفر شاحبًا ويسبب ضعفًا أو عُسْر تنَفُّس).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتبع نظامًا غذائيًّا منخفض الصوديوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت أو كنت قد عانيت سابقًا من مجموعة من أيٍّ من الأعراض التَّالية: الطفح الجلدي، احمرار الجلد، ظهور بثور بالشفتين، العينين والفم، تقشُّر الجلد، حمى مرتفعة، أعراض شبيهة بأعراض الإنفلونزا، ارتفاع مستويات أنزيمات الكبد والذي يتم ملاحظته في اختبارات الدَّم وازدياد أحد أنواع خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات) وتضخم العقد الليمفاوية (علامات الإصابة بالتفاعلات الجلدية الشديدة، انظر أيضًا قسم 4 &quot;الآثار الجانبية المُحتملة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا كنت بحاجة إلى الخضوع لأحد اختبارات الدَّم أو البول</strong></p><p dir="RTL">قد تحتاج إلى الخضوع لاختبارات دم منتظمة إذا كان يتم إعطاؤك عقار ميجيون<sup>&reg;</sup> لفترة طويلة. قد يُؤثر عقار ميجيون<sup>&reg;</sup> على نتائج اختبارات البول للكشف عن السُّكَّر واختبار الدم الذي يُعرف باختبار كومبس. إذا كنت ستخضع للاختبارات:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبر الشخص الذي سيتولى سحب العينة أنه قد تم إعطاؤك عقار ميجيون<sup>&reg;</sup>.</p><p dir="RTL">إذا كنت مُصابًا بمرض السُّكَّرِي أو كنت بحاجة إلى مراقبة مستوى الجلوكوز لديك في الدَّم، ينبغي عليك عدم استخدام بعض أنظمة مراقبة مستوى الجلوكوز في الدَّم التي قد تُقدر مستوى الجلوكوز في الدَّم بشكل غير صحيح أثناء تلقيك سيفترياكسون. اطلع على تعليمات الاستخدام وأخبِر طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك إذا كنت تستخدم مثل هذه الأنظمة. ينبغي استخدام طرق بديلة للاختبار إذا لزم الأمر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال</strong></p><p dir="RTL">تحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة) الخاص(ة) بك قبل أن يتم إعطاء طفلك/ طفلتك عقار ميجيون<sup>&reg;</sup> في الحالات الآتية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حال تم إعطاء طفلك/طفلتك مؤخرًا أو سيتم إعطاؤه/إعطاؤها منتجًا يحتوي على الكالسيوم في الوريد.</p><p dir="RTL"><strong>استخدام أدوية أخرى مع عقار ميجيون<sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">يُرجى إخبار طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. على وجه الخصوص، أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول أيًّا من الأدوية التَّالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوعٍ من المضادات الحيوية يُدعى أمينُوجْليكُوزيد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادٍّ حيويٍّ يُدعى كلورامفينيكول (يُستخدَم لعلاج العدوى، وخاصةً في العينين).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل، فاستشيري طبيبكِ قبل تلقي هذا الدَّواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيأخذ الطبيب بعين الاعتبار فائدة خضوعكِ للعلاج بعقار ميجيون<sup>&reg;</sup> مقابل خطر ذلك على رضيعك.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يمكن أن يسبب عقار ميجيون<sup>&reg;</sup> دوخة. إذا شعرت بالدوخة، فتجنب ممارسة القيادة أو استخدام أية أدوات أو آلات. تحدَّث إلى طبيبك إذا كنت تعاني من هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار ميجيون<sup>&reg;</sup></strong><strong> على الصوديوم</strong></p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><em>&nbsp;0.5 جرام مسحوق لإعداد محلول للحقن:</em></p><p dir="RTL">يحتوي هذا الدَّواء على 42 مجم من الصوديوم (المُكَوِّن الأساسي لملح الطعام) بكل زجاجة. يُعادل ذلك 2.1٪ من كمية الصوديوم القصوى المُوصى للبالغ بتناوُلها يوميًّا في الغذاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><em>1 جرام مسحوق لإعداد محلول للحقن:</em></p><p dir="RTL">يحتوي هذا الدَّواء على 83 مجم من الصوديوم (المُكَوِّن الأساسي لملح الطعام) بكل زجاجة. يُعادل ذلك 4.2٪ من كمية الصوديوم القصوى المُوصى للبالغ بتناوُلها يوميًّا في الغذاء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادة ما يتم إعطاء عقار ميجيون<sup>&reg;</sup> من قِبَل الطبيب أو الممرض(ة). يمكن إعطاؤه على هيئة تنقيط (تسريب وريدي) أو على هيئة حقن في الوريد أو العضل مباشرة. يتم إعداد عقار ميجيون<sup>&reg;</sup> من قبل الطبيب، الصيدلي أو الممرض(ة) ولن يتم خلطه مع الحقن التي تحتوي على الكالسيوم أو إعطاؤه لك في نفس الوقت معها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة المعتادة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر طبيبك الجرعة المناسبة لك من عقار ميجيون<sup>&reg;</sup>. ستعتمد الجرعة على شدة العدوى ونوعها، ما إذا كنت تستخدم أيَّ مضادات حيوية أخرى أم لا، وزنك وعمرك، مدى كفاءة وظائف الكُلى والكبد لديك. يعتمد عدد الأيام أو الأسابيع التي سيتم إعطاؤك خلالها عقار ميجيون<sup>&reg;</sup> على نوع العدوى التي تعاني منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغون وكبار السن والأطفال بعمر 12 عامًا فأكثر بوزن جسم يبلغ 50 كيلو جرامًا (كجم) أو أكثر:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما يتراوح بين جرام واحد وجرامين مرة واحدة يوميًّا استنادًا إلى شدة العدوى ونوعها. سيعطيك طبيبك جرعة أعلى إذا كنت تعاني من عدوى شديدة (ما يصل إلى 4 جرامات مرة واحدة يوميًّا). إذا زادت جرعتك اليومية عن جرامين، يمكنك تلقيها على هيئة جرعة واحدة مرة واحدة يوميًّا أو على هيئة جرعتين منفصلتين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>حديثو الولادة، الرُّضع والأطفال ممن تتراوح أعمارهم بين 15 يومًا و12 عامًا بوزن جسم أقل من 50 كجم:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50-80 مجم من عقار ميجيون<sup>&reg;</sup> لكل كجم من وزن جسم الطفل مرة واحدة يوميًّا استنادًا إلى شدة العدوى ونوعها. في حال كنت تعاني من عدوى شديدة، سيعطيك طبيبك جرعة أعلى تصل إلى 100 مجم لكل كجم من وزن الجسم بحد أقصاه 4 جرامات مرة واحدة يوميًّا. إذا زادت جرعتك اليومية عن جرامين، يمكنك تلقيها على هيئة جرعة واحدة مرة واحدة يوميًّا أو على هيئة جرعتين منفصلتين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي إعطاء الأطفال ممن تبلغ أوزان أجسامهم 50 كجم أو أكثر جرعة البالغين المُعتادة.</p><p dir="RTL"><strong>حديثو الولادة (0-14 يومًا)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20 &ndash; 50 مجم من عقار ميجيون<sup>&reg;</sup> لكل كجم من وزن جسم الطفل مرة واحدة يوميًّا استنادًا إلى شدة العدوى ونوعها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينبغي ألا تتعدى الجرعة اليومية القصوى 50 مجم لكل كجم من وزن الرضيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشاكل في الكبد والكُلى</strong></p><p dir="RTL">قد يتم إعطاؤك جرعة مختلفة عن الجرعة المُعتادة. سيقرر طبيبك الكمية التي ستحتاجها من عقار ميجيون<sup>&reg;</sup> وسيقوم بفحصك عن كثب استنادًا إلى شدة المرض الكبدي والكُلوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تم إعطاؤك كمية أكبر مما ينبغي من عقار ميجيون<sup>&reg;</sup></strong></p><p dir="RTL">إذا تلقيت عن طريق الخطأ كمية أكبر من الجرعة الموصوفة لك، فاتصل بطبيبك أو بأقرب مستشفى على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أغفلت استخدام عقار ميجيون<sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">إذا أغفلت تلقي إحدى الحقن، ينبغي عليك تلقيها بأسرع وقت ممكن. مع ذلك، إذا كان موعد الحقنة التَّالية قد اقترب، فتجاوز الحقنة التي أغفلت تلقيها. لا تتلقى جرعة مضاعفة (حقنتين في الوقت نفسه) لتعويض جرعة أغفلتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام عقار ميجيون<sup>&reg;</sup></strong><strong> </strong></p><p dir="RTL">لا تتوقف عن تلقي عقار ميجيون<sup>&reg;</sup> ما لم يأمرك طبيبك بذلك. إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الممرض(ة) الخاص(ة) بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرغم من عدم حدوثها لدى الجميع. قد تحدث الآثار الجانبية التَّالية مع استخدام هذا الدَّواء:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات حساسية شديدة (غير معروفة، لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</strong></p><p dir="RTL">أخبر الطبيب على الفور إذا عانيت من تفاعل حساسية شديد.</p><p dir="RTL">قد تشمل العلامات ما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّمًا مفاجئًا بالوجه، الحَلْق، الشفتين أو الفم. قد يسبب ذلك صعوبة في التَّنفس أو البلع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّمًا مفاجئًا باليدين، القدمين والكاحلين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات جلدية شديدة (غير معروفة، لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</strong></p><p dir="RTL">أخبر الطبيب على الفور إذا أُصِبت بتفاعل جلدي شديد.</p><p dir="RTL">قد تشمل العلامات ما يلي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفحًا جلديًّا شديدًا يتطور سريعًا مصحوبًا ببثور بالجلد أو تقشُّر الجلد وربما تظهر بثور بالفم (متلازمة ستيفنز جونسون وانحلال البشرة النخري التَّسَمُّمِيّ).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مجموعة من أيٍّ من الأعراض التَّالية: طفح جلدي منتشر على نطاق واسع، ارتفاع درجة حرارة الجسم، ارتفاع مستوى أنزيمات الكبد، اضطرابات في الدَّم (كثرة خلايا اليُوزينِيَّات)، تضخم العقد الليمفاوية وأعضاء الجسم الأخرى (التفاعل الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية الذي يُعرف أيضًا بمتلازمة فرط الحساسية تجاه العقار).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل ياريش-هِيكِسْهايمِر الذي يسبب حُمَّى، قشعريرة، صداعًا، ألمًا عضليًّا وطفحًا جلديًّا عادة ما يزول تلقائيًّا. يحدث ذلك بعد فترة قصيرة من بدء الخضوع لسيفترياكسون لعلاج عدوى الملتوية مثل مرض لايم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المُحتمَلة الأخرى:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات بخلايا الدَّم البيضاء لديك (مثل: انخفاض خلايا الدَّم البيضاء وزيادة الحمضات) والصفائح الدَّموية (انخفاض الصفائح الدَّموية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز رخو أو إِسْهال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبارات الدَّم الخاصة بوظائف الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية (على سبيل المثال، السُّلَاق).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدَّم البيضاء (قلة خلايا المحببات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدَّم الحمراء (فقر الدَّم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في طريقة تجلط الدَّم لديك. قد تشمل العلامات سهولة الإصابة بكدمات وألمًا في المفاصل وتورمها.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالإعياء أو الإصابة بإعياء.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو شعور بحرقة على طول الوريد حيث تم إعطاء عقار ميجيون<sup>&reg;</sup>. ألم حيث تم إعطاء الحَقن.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة (حُمَّى).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية لاختبار وظائف الكُلى (ارتفاع الكرياتينين في الدَّم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأمعاء الغليظة (القولون). تشمل العلامات إِسْهالًا، مصحوبًا عادةً بدم ومخاط، ألمًا في المعدة وحُمَّى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التَّنفس (التشنج القصبي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي متكتل (شرى) قد يغطي أجزاء كثيرة من جسمك، الشعور بحكة وتورم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم أو سكر لديك في البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (تراكم السوائل).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتِجَاف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; نادرًا ما قد يسبب الخضوع للعلاج بسيفترياكسون تدنيًا في الوعي وحركات غير طبيعية وهِياجًا وتشنُّجات، خاصةً في المرضى من كبار السن الذين يعانون من مشاكل خطيرة في الكُلى أو الجهاز العصبي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بعدوى ثانوية قد لا تستجيب للمضاد الحيوي الذي تم وصفه سابقًا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شكل من أشكال فقر الدَّم يحدث فيه تكسير لخلايا الدَّم الحمراء (فقر الدَّم الانحلالي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض شديد في خلايا الدَّم البيضاء (ندرة خلايا المحببات).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشنجات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوار (شعور بالدوران).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس. تشمل العلامات ألمًا شديدًا في المعدة يمتد إلى ظهرك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البطانة المخاطية بالفم (التهاب الفم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب اللسان. تشمل العلامات تورمًا واحمرارًا وألمًا باللسان.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالمرارة و/أو الكبد قد تسبب ألمًا وغثيانًا وقيئًا واصفرار الجلد وحكة وبولًا داكنًا على غير العادة وبرازًا لونه شبيه بالطين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة عصبية قد تحدث لدى حديثي الولادة المُصابين بيرقان شديد (اليرقان النووي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكُلى ناجمة عن ترسب سيفترياكسون الكالسيوم. قد يكون هناك ألم عند التبول أو انخفاض في ناتج البول.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتيجة إيجابية كاذبة باختبار كومبس (اختبار خاص ببعض مشاكل الدَّم).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتيجة إيجابية كاذبة فيما يخص الجالاكتوزيمية (تراكم غير طبيعي لسكر الجالاكتوز).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتداخل عقار ميجيون<sup>&reg;</sup> مع بعض أنواع اختبارات الجلوكوز في الدَّم - يُرجى مراجعة طبيبك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على العبوة الكرتونية والملصق بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُخزَّن في درجة حرارة تتعدى 30 درجة مئوية.</p><p dir="RTL">يُخزَّن داخل العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">المحلول المُعد للاستخدام:</p><p dir="RTL">بمجرد إذابة المسحوق، ينبغي استخدام المحلول على الفور أو حفظه في الثلاجة في درجة حرارة تتراوح بين 2 و 8 درجات مئوية وينبغي التَّخلص منه بعد انقضاء 48 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عقار ميجيون<sup>&reg;</sup> 0.5 جرام مسحوق ومُذيب لإعداد محلول للحقن:</p><p dir="RTL">المسحوق: المادة الفعَّالة هي سيفترياكسون.</p><p dir="RTL">تحتوي كل زجاجة على الآتي: 0.5 جرام من سيفترياكسون (على هيئة سيفترياكسون مائي ثنائي الصوديوم)</p><p dir="RTL">يحتوي كل أمبول من هيدروكلوريد الليدوكائين على الآتي: هيدروكلوريد الليدوكائين 1٪ (20 مجم/2 مللي لتر)، ماء للحقن، كربونات هيدروجين الصوديوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار ميجيون<sup>&reg;</sup> 1 جرام مسحوق ومُذيب لإعداد محلول للحقن:</p><p dir="RTL">المسحوق: المادة الفعَّالة هي سيفترياكسون.</p><p dir="RTL">تحتوي كل زجاجة على الآتي: 1 جرام من سيفترياكسون (على هيئة سيفترياكسون مائي ثنائي الصوديوم)</p><p dir="RTL">يحتوي كل أمبول من هيدروكلوريد الليدوكائين على الآتي: هيدروكلوريد الليدوكائين 1٪ (35 مجم/ 3.5 مللي لترات)، ماء للحقن، كربونات هيدروجين الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما شكل عقار ميجيون<sup>&reg;</sup>؟ وما محتويات العبوة؟</strong></p><p dir="RTL">مسحوق ومُذيب لإعداد محلول للحقن/ للتَّسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لون المسحوق أبيض يميل إلى الأصفر.</p><p dir="RTL">المُذيب عبارة عن محلول صافٍ وعديم اللون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أحجام العبوات:</p><p dir="RTL">زجاجة واحدة + أمبول واحد</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp; شركة ساندوز المحدودة، كوندل، النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر  2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Megion 0.5 g powder and solvent for solution for injection	
 Megion 1 g powder and solvent for solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Megion 0.5 g powder and solvent for solution for i.m. injection:
Each vial contains: 0.5 g ceftriaxone (as ceftriaxone disodium, hydrated) 
Each ampoule contains: 1% (20 mg/2 ml) lidocaine hydrochloride solution as a solvent 

Megion 0.5 g powder and solvent for solution for i.v. injection: Each vial contains: 0.5 g ceftriaxone (as disodium 3.5 hydrate) 
One solvent ampoule contains: 5 ml water for injections  

Megion 1 g powder and solvent for solution for i.m.  injection:
Each vial contains: 1 g ceftriaxone (as ceftriaxone disodium, hydrated)
Each ampoule contains: 1% (35 mg/3.5 ml) lidocaine hydrochloride solution as a solvent 

Megion 1 g powder and solvent for solution for i.v. injection/infusion:
Each vial contains: 1 g ceftriaxone (as ceftriaxone disodium, hydrated) 
Each ampoule contains: 10 ml water for injection as a solvent

Excipients with known effect:
Each vial of ceftriaxone 0.5 g contains 1.8 mmol sodium (42 mg sodium).
Each vial of ceftriaxone 1 g contains 3.6 mmol sodium (83 mg sodium).

For the full list of excipients, see section 6.1.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection/infusion.

The powder is coloured white to yellowish.
The solvent is a clear and colourless solution.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Megion is indicated for the treatment of the following infections in adults and children including term neonates (from birth):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial Meningitis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community acquired pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospital acquired pneumonia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute otitis media</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Intra-abdominal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections (including pyelonephritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of bones and joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissue infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gonorrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syphilis</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bacterial endocarditis</p><p>&nbsp;</p><p>Megion may be used:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of acute exacerbations of chronic obstructive pulmonary disease in adults</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of disseminated Lyme borreliosis (early (stage II) and late (stage III)) in adults and children including neonates from 15 days of age.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For pre-operative prophylaxis of surgical site infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above</p><p>&nbsp;</p><p>Megion should be co-administered with other antibacterial agents whenever the possible range of causative bacteria would not fall within its spectrum (see section 4.4).</p><p>&nbsp;</p><p>Consideration should be given to official guidelines on the appropriate use of antibacterial agents.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p>The dose depends on the severity, susceptibility, site and type of infection and on the age and hepato- renal function of the patient.</p><p>&nbsp;</p><p>The doses recommended in the tables below are the generally recommended doses in these indications. In particularly severe cases, doses at the higher end of the recommended range should be considered.</p><p>&nbsp;</p><p><em><u>A</u></em><em><u>dults and children over 12 years of age (&ge; 50 kg)</u></em></p><p><em>&nbsp;</em></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ceftriaxone Dosage*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment frequency**</strong></p></td><td style="vertical-align:top"><p><strong>Indications</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>1-2 g</p></td><td rowspan="4" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Acute exacerbations of chronic obstructive pulmonary disease</p></td></tr><tr><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>2 g</p></td><td rowspan="3" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Hospital acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Infections of bones and joints</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>2-4 g</p></td><td rowspan="3" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial endocarditis</p></td></tr><tr><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr></tbody></table><p>In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>**&nbsp;&nbsp; Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.</p><p>&nbsp;</p><p>Indications for adults and children over 12 years of age (&ge; 50 kg) that require specific dosage schedules:</p><p>&nbsp;</p><p>Acute otitis media</p><p>A single intramuscular dose of Megion 1-2 g can be given. Limited data suggest that in cases where the patient is severely ill or previous therapy has failed, Megion may be effective when given as an intramuscular dose of 1-2 g daily for 3 days.</p><p>&nbsp;</p><p>Pre-operative prophylaxis of surgical site infections</p><p>2 g as a single pre-operative dose.</p><p>&nbsp;</p><p>Gonorrhoea</p><p>500 mg as a single intramuscular dose.</p><p>&nbsp;</p><p>Syphilis</p><p>The generally recommended doses are 500 mg-1 g once daily increased to 2 g once daily for neurosyphilis for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on limited data. National or local guidance should be taken into consideration.</p><p>&nbsp;</p><p>Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])</p><p>2 g once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.</p><p>&nbsp;</p><p><em><u>P</u></em><em><u>aediatric population</u></em></p><p>&nbsp;</p><p><em>N</em><em>eonates, infants and children 15 days to 12 years of age (&lt; 50 kg)</em></p><p>For children with bodyweight of 50 kg or more, the usual adult dosage should be given.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ceftriaxone dosage*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment frequency**</strong></p></td><td style="vertical-align:top"><p><strong>Indications</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>50-80 mg/kg</p></td><td rowspan="4" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Hospital acquired pneumonia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>50-100 mg/kg</p><p>(Max 4 g)</p></td><td rowspan="3" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Infections of bones and joints</p></td></tr><tr><td style="vertical-align:top"><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td style="vertical-align:top"><p>80-100 mg/kg</p><p>(max 4 g)</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Bacterial meningitis</p></td></tr><tr><td style="vertical-align:top"><p>100 mg/kg</p><p>(max 4 g)</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Bacterial endocarditis</p></td></tr></tbody></table><p>*&nbsp;&nbsp;&nbsp;&nbsp; In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>**&nbsp;&nbsp; Twice daily (12 hourly) administration may be considered where doses greater than 2 g daily are administered.</p><p>&nbsp;</p><p>Indications for neonates, infants and children 15 days to 12 years (&lt; 50 kg) that require specific dosage schedules:</p><p>&nbsp;</p><p>Acute otitis media</p><p>For initial treatment of acute otitis media, a single intramuscular dose of Megion 50 mg/kg can be given. Limited data suggest that in cases where the child is severely ill or initial therapy has failed, Megion may be effective when given as an intramuscular dose of 50 mg/kg daily for 3 days.</p><p>&nbsp;</p><p>Pre-operative prophylaxis of surgical site infections</p><p>50-80 mg/kg as a single pre-operative dose.</p><p>&nbsp;</p><p>Syphilis</p><p>The generally recommended doses are 75-100 mg/kg (max 4 g) once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local</p><p>guidance should be taken into consideration.</p><p>&nbsp;</p><p>Disseminated Lyme borreliosis (early [Stage II] and late [Stage III])</p><p>50&ndash;80 mg/kg once daily for 14-21 days. The recommended treatment durations vary and national or local guidelines should be taken into consideration.</p><p>&nbsp;</p><p><em>N</em><em>eonates 0-14 days</em></p><p>Megion is contraindicated in premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Ceftriaxone dosage*</strong></p></td><td style="vertical-align:top"><p><strong>Treatment frequency</strong></p></td><td style="vertical-align:top"><p><strong>Indications</strong></p></td></tr><tr><td rowspan="7" style="vertical-align:top"><p>20-50 mg/kg</p></td><td rowspan="7" style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Intra-abdominal infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections (including pyelonephritis)</p></td></tr><tr><td style="vertical-align:top"><p>Community acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Hospital acquired pneumonia</p></td></tr><tr><td style="vertical-align:top"><p>Infections of bones and joints</p></td></tr><tr><td style="vertical-align:top"><p>Management of neutropenic patients with fever that is suspected to be due to a bacterial infection</p></td></tr><tr><td style="vertical-align:top"><p>50 mg/kg</p></td><td style="vertical-align:top"><p>Once daily</p></td><td style="vertical-align:top"><p>Bacterial meningitis&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Bacterial endocarditis&nbsp; &nbsp; &nbsp;&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>*&nbsp; &nbsp;In documented bacteraemia, the higher end of the recommended dose range should be considered.</p><p>A maximum daily dose of 50 mg/kg should not be exceeded.</p><p>Indications for neonates 0-14 days that require specific dosage schedules: Acute otitis media</p><p>For initial treatment of acute otitis media, a single intramuscular dose of Megion 50 mg/kg can be given.</p><p>&nbsp;</p><p>Pre-operative prophylaxis of surgical site infections</p><p>20-50 mg/kg as a single pre-operative dose.</p><p>&nbsp;</p><p>Syphilis</p><p>The generally recommended dose is 50 mg/kg once daily for 10-14 days. The dose recommendations in syphilis, including neurosyphilis, are based on very limited data. National or local guidance should be taken into consideration.</p><p>&nbsp;</p><p><em><u>D</u></em><em><u>uration of therapy</u></em></p><p>&nbsp;</p><p>The duration of therapy varies according to the course of the disease. As with antibiotic therapy in general, administration of ceftriaxone should be continued for 48 - 72 hours after the patient has become afebrile or evidence of bacterial eradication has been achieved.</p><p>&nbsp;</p><p><em><u>O</u></em><em><u>l</u></em><em><u>der people</u></em></p><p>&nbsp;</p><p>The dosages recommended for adults require no modification in older people provided that renal and hepatic function is satisfactory.</p><p>&nbsp;</p><p><em><u>P</u></em><em><u>atients with hepatic impairment</u></em></p><p>Available data do not indicate the need for dose adjustment in mild or moderate liver function impairment provided renal function is not impaired.</p><p>&nbsp;</p><p>There are no study data in patients with severe hepatic impairment (see section 5.2).</p><p>&nbsp;</p><p><em><u>P</u></em><em><u>atients with renal impairment</u></em></p><p>In patients with impaired renal function, there is no need to reduce the dosage of ceftriaxone provided hepatic function is not impaired. Only in cases of preterminal renal failure (creatinine clearance &lt; 10 ml/min) should the ceftriaxone dosage not exceed 2 g daily.</p><p>In patients undergoing dialysis no additional supplementary dosing is required following the dialysis. Ceftriaxone is not removed by peritoneal- or haemodialysis. Close clinical monitoring for safety and efficacy is advised.</p><p>&nbsp;</p><p><em><u>P</u></em><em><u>atients with severe hepatic and renal impairment</u></em></p><p>&nbsp;</p><p>In patients with both severe renal and hepatic dysfunction, close clinical monitoring for safety and efficacy is advised.</p><p>&nbsp;</p><p><u>M</u><u>ethod of administration</u></p><p><em><u>Intramuscular administration</u></em></p><p>Megion can be administered by deep intramuscular injection. Intramuscular injections should be injected well within the bulk of a relatively large muscle and not more than 1 g should be injected at one site.</p><p>As the solvent used is lidocaine, the resulting solution should never be administered intravenously (see section 4.3). The information in the Summary of Product Characteristics of lidocaine should be considered.</p><p>&nbsp;</p><p><em><u>Intravenous administration</u></em></p><p>Megion can be administered by intravenous infusion over at least 30 minutes (preferred route) or by slow intravenous injection over 5 minutes. Intravenous intermittent injection should be given over 5 minutes preferably in larger veins. Intravenous doses of 50 mg/kg or more in infants and children up to 12 years of age should be given by infusion. In neonates, intravenous doses should be given over 60 minutes to reduce the potential risk of bilirubin encephalopathy (see section 4.3 and 4.4). Intramuscular administration should be considered when the intravenous route is not possible or less appropriate for the patient. For doses greater than 2 g intravenous administration should be used.</p><p>&nbsp;</p><p>Ceftriaxone is contraindicated in neonates (&le; 28 days) if they require (or are expected to require) treatment with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of ceftriaxone-calcium (see section 4.3).</p><p>&nbsp;</p><p>Diluents containing calcium, (e.g. Ringer&rsquo;s solution or Hartmann&rsquo;s solution), should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Therefore, ceftriaxone and calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4 and 6.2).</p><p>&nbsp;</p><p>For pre-operative prophylaxis of surgical site infections, ceftriaxone should be administered 30-90 minutes prior to surgery.</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to ceftriaxone, to any other cephalosporin or to any of the excipients listed in section 6.1.
History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins, monobactams and carbapenems).

Ceftriaxone is contraindicated in:
Premature neonates up to a postmenstrual age of 41 weeks (gestational age + chronological age)*
Full-term neonates (up to 28 days of age):
-	with hyperbilirubinaemia, jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which bilirubin binding is likely to be impaired*
-	if they require (or are expected to require) intravenous calcium treatment, or calcium-containing infusions due to the risk of precipitation of a ceftriaxone-calcium salt (see sections 4.4, 4.8 and 6.2).
* In vitro studies have shown that ceftriaxone can displace bilirubin from its serum albumin binding sites leading to a possible risk of bilirubin encephalopathy in these patients.

Contraindications to lidocaine must be excluded before intramuscular injection of ceftriaxone when lidocaine solution is used as a solvent (see section 4.4). See information in the Summary of Product Characteristics of lidocaine, especially contraindications.
Ceftriaxone solutions containing lidocaine should never be administered intravenously.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>H</u><u>y</u><u>persensitivity reactions</u></p><p>&nbsp;</p><p>As with all beta-lactam antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported (see section 4.8). In case of severe hypersensitivity reactions, treatment with ceftriaxone must be discontinued immediately and adequate emergency measures must be initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity reactions to ceftriaxone, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if ceftriaxone is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents.</p><p>&nbsp;</p><p>Severe cutaneous adverse reactions (Stevens Johnson syndrome or Lyell&rsquo;s syndrome/toxic epidermal necrolysis<strong><u> </u></strong>and drug reaction with eosinophilia and systemic symptoms (DRESS)) which can be life-threatening or fatal) have been reported in association of ceftriaxone treatment; however, the frequency of these events is not known (see section 4.8).</p><p><u>&nbsp;</u></p><p><u>&nbsp;</u></p><p><u>Jarisch-Herxheimer reaction (JHR)</u></p><p>Some patients with spirochete infections may experience a Jarisch-Herxheimer reaction (JHR) shortly after ceftriaxone treatment is started. JHR is usually a self &ndash; limiting condition or can be managed by symptomatic treatment.&nbsp; The antibiotic treatment should not be discontinued if such reaction occurs.</p><p><u>Encephalopathy</u></p><p>Encephalopathy has been reported with the use of ceftriaxone (see section 4.8), particularly in elderly patients with severe renal impairment (see section 4.2) or central nervous system disorders. If ceftriaxone-associated encephalopathy is suspected (e.g. decreased level of consciousness, altered mental state, myoclonus, convulsions), discontinuation of ceftriaxone should be considered.</p><p>&nbsp;</p><p><u>I</u><u>nteraction with calcium containing products</u></p><p>&nbsp;</p><p>Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and full-term neonates aged less than 1 month have been described. At least one of them had received ceftriaxone and calcium at different times and through different intravenous lines. In the available scientific data, there are no reports of confirmed intravascular precipitations in patients, other than neonates, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing products. <em>In vitro </em>studies demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium compared to other age groups.</p><p>&nbsp;</p><p>In patients of any age ceftriaxone must not be mixed or administered simultaneously with any calcium-containing intravenous solutions, even via different infusion lines or at different infusion sites. However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be administered sequentially one after another if infusion lines at different sites are used or if the infusion lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid precipitation. In patients requiring continuous infusion with calcium-containing total parenteral nutrition (TPN) solutions, healthcare professionals may wish to consider the use of alternative antibacterial treatments which do not carry a similar risk of precipitation. If the use of ceftriaxone is considered necessary in patients requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously, albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be stopped for the period of ceftriaxone infusion and the infusion lines flushed between solutions (see sections 4.3, 4.8, 5.2 and 6.2).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>Safety and effectiveness of Megion in neonates, infants and children have been established for the dosages described under Posology and Method of Administration (see section 4.2). Studies have shown that ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin.</p><p>Megion is contraindicated in premature and full-term neonates at risk of developing bilirubin encephalopathy (see section 4.3).</p><p>&nbsp;</p><p><u>I</u><u>m</u><u>m</u><u>une mediated haemolytic anaemia</u></p><p>&nbsp;</p><p>An immune mediated haemolytic anaemia has been observed in patients receiving cephalosporin class antibacterials including Megion (see section 4.8). Severe cases of haemolytic anaemia, including fatalities, have been reported during Megion treatment in both adults and children.</p><p>&nbsp;</p><p>If a patient develops anaemia while on ceftriaxone, the diagnosis of a cephalosporin<strong><em>-</em></strong>associated anaemia should be considered and ceftriaxone discontinued until the aetiology is determined.</p><p>&nbsp;</p><p><u>L</u><u>ong term treatment</u></p><p>&nbsp;</p><p>During prolonged treatment complete blood count should be performed at regular intervals. <u>Colitis/Overgrowth of non-susceptible microorganisms</u></p><p>&nbsp;</p><p>Antibacterial agent-associated colitis and pseudo-membranous colitis have been reported with nearly all antibacterial agents, including ceftriaxone, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftriaxone (see section 4.8). Discontinuation of therapy with ceftriaxone and the administration of specific treatment for <em>Clostridium difficile </em>should be considered. Medicinal products that inhibit peristalsis should not be given.</p><p>Superinfections with non-susceptible micro-organisms may occur as with other antibacterial agents.</p><p>&nbsp;</p><p><u>Severe renal and hepatic insufficiency</u></p><p>&nbsp;</p><p>In severe renal and hepatic insufficiency, close clinical monitoring for safety and efficacy is advised (see section 4.2).</p><p>&nbsp;</p><p><u>I</u><u>nterference with serological testing</u></p><p>&nbsp;</p><p>Interference with Coombs tests may occur, as Megion may lead to false-positive test results. Megion can also lead to false-positive test results for galactosaemia (see section 4.8).</p><p>Non-enzymatic methods for the glucose determination in urine may give false-positive results. Urine glucose determination during therapy with Megion should be done enzymatically (see section 4.8).</p><p>&nbsp;</p><p>The presence of ceftriaxone may falsely lower estimated blood glucose values obtained with some blood glucose monitoring systems. Please refer to instructions for use for each system. Alternative testing methods should be used if necessary.</p><p>&nbsp;</p><p><u>A</u><u>ntibacterial spectrum</u></p><p>&nbsp;</p><p>Ceftriaxone has a limited spectrum of antibacterial activity and may not be suitable for use as a single agent for the treatment of some types of infections unless the pathogen has already been confirmed (see section 4.2). In polymicrobial infections, where suspected pathogens include organisms resistant to ceftriaxone, administration of an additional antibiotic should be considered.</p><p>&nbsp;</p><p><u>U</u><u>se of lidocaine</u></p><p>&nbsp;</p><p>In case a lidocaine solution is used as a solvent<strong><em>, </em></strong>ceftriaxone solutions must only be used for intramuscular injection. Contraindications to lidocaine, warnings and other relevant information as detailed in the Summary of Product Characteristics of lidocaine must be considered before use (see section 4.3). The lidocaine solution should never be administered intravenously.</p><p><u>&nbsp;</u></p><p><u>B</u><u>il</u><u>i</u><u>ary lithiasis</u></p><p>&nbsp;</p><p>When shadows are observed on sonograms, consideration should be given to the possibility of precipitates of calcium ceftriaxone. Shadows, which have been mistaken for gallstones, have been detected on sonograms of the gallbladder and have been observed more frequently at ceftriaxone doses of 1 g per day and above. Caution should be particularly considered in the paediatric population. Such precipitates disappear after discontinuation of ceftriaxone therapy. Rarely precipitates of calcium ceftriaxone have been associated with symptoms. In symptomatic cases, conservative nonsurgical management is recommended and discontinuation of ceftriaxone treatment should be considered by the physician based on specific benefit risk assessment (see section 4.8).</p><p>&nbsp;</p><p><u>B</u><u>il</u><u>i</u><u>ary stasis</u></p><p>&nbsp;</p><p>Cases of pancreatitis, possibly of biliary obstruction aetiology, have been reported in patients treated with Megion (see section 4.8). Most patients presented with risk factors for biliary stasis and biliary sludge e.g. preceding major therapy, severe illness and total parenteral nutrition. A trigger or cofactor of Megion-related biliary precipitation cannot be ruled out.</p><p>&nbsp;</p><p><u>R</u><u>enal lithiasis</u></p><p>&nbsp;</p><p>Cases of renal lithiasis have been reported, which is reversible upon discontinuation of ceftriaxone (see section 4.8). In symptomatic cases, sonography should be performed. Use in patients with history of renal lithiasis or with hypercalciuria should be considered by the physician based on specific benefit risk assessment.</p><p>&nbsp;</p><p><u>Megion</u><u>&nbsp;contains sodium</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em>0.5 g </em><em>powder for solution for injection:</em></p><p>This medicinal product contains 42 mg sodium per vial, equivalent to 2.1% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p><p><em>1 g </em><em>powder for solution for injection:</em></p><p>This medicinal product contains 83 mg sodium per vial, equivalent to 4.2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p><p>&nbsp;</p><p><em>1 g </em><em>powder for solution for injection/infusion:</em></p><p>This medicinal product contains 83 mg sodium per vial, equivalent to 4.2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Calcium-containing diluents, such as Ringer&rsquo;s solution or Hartmann&rsquo;s solution, should not be used to reconstitute Megion vials or to further dilute a reconstituted vial for intravenous administration because a precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed with calcium-containing solutions in the same intravenous administration line. Ceftriaxone must not be administered simultaneously with calcium-containing intravenous solutions, including continuous calcium-containing infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates, ceftriaxone and calcium-containing solutions may be administered sequentially of one another if the infusion lines are thoroughly flushed between infusions with a compatible fluid. <em>In vitro </em>studies using adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased risk of precipitation of ceftriaxone-calcium (see sections 4.2, 4.3, 4.4, 4.8 and 6.2).</p><p>&nbsp;</p><p>Concomitant use with oral anticoagulants may increase the anti-vitamin K effect and the risk of bleeding. It is recommended that the International Normalised Ratio (INR) is monitored frequently and the posology of the anti-vitamin K drug adjusted accordingly, both during and after treatment with ceftriaxone (see section 4.8).</p><p>&nbsp;</p><p>There is conflicting evidence regarding a potential increase in renal toxicity of aminoglycosides when used with cephalosporins. The recommended monitoring of aminoglycoside levels (and renal function) in clinical practice should be closely adhered to in such cases.</p><p>&nbsp;</p><p>In an <em>in-vitro </em>study antagonistic effects have been observed with the combination of chloramphenicol and ceftriaxone. The clinical relevance of this finding is unknown.</p><p>&nbsp;</p><p>There have been no reports of an interaction between ceftriaxone and oral calcium-containing products or interaction between intramuscular ceftriaxone and calcium-containing products (intravenous or oral).</p><p>&nbsp;</p><p>In patients treated with ceftriaxone, the Coombs&#39; test may lead to false-positive test results.</p><p>Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia.</p><p>&nbsp;</p><p>Likewise, non-enzymatic methods for glucose determination in urine may yield false-positive results. For this reason, glucose level determination in urine during therapy with ceftriaxone should be carried out enzymatically.</p><p>&nbsp;</p><p>No impairment of renal function has been observed after concurrent administration of large doses of ceftriaxone and potent diuretics (e.g. furosemide).</p><p>&nbsp;</p><p>Simultaneous administration of probenecid does not reduce the elimination of ceftriaxone.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Ceftriaxone crosses the placental barrier. There are limited amounts of data from the use of ceftriaxone in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to embryonal/foetal, perinatal and postnatal development (see section 5.3). Ceftriaxone should only be administered during pregnancy and in particular in the first trimester of pregnancy if the benefit outweighs the risk.</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>eastfeeding</u></p><p>&nbsp;</p><p>Ceftriaxone is excreted into human milk in low concentrations but at therapeutic doses of ceftriaxone no effects on the breastfed infants are anticipated. However, a risk of diarrhoea and fungal infection of the mucous membranes cannot be excluded. The possibility of sensitisation should be taken into account. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ceftriaxone therapy, taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Reproductive studies have shown no evidence of adverse effects on male or female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>During treatment with ceftriaxone, undesirable effects may occur (e.g. dizziness), which may influence the ability to drive and use machines (see section 4.8). Patients should be cautious when driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most frequently reported adverse reactions for ceftriaxone are eosinophilia, leucopenia, thrombocytopenia, diarrhoea, rash, and hepatic enzymes increased.</p><p>Data to determine the frequency of ceftriaxone ADRs was derived from clinical trials. The following convention has been used for the classification of frequency:</p><p>Very common (&ge; 1/10)</p><p>Common (&ge; 1/100 - &lt; 1/10)</p><p>Uncommon (&ge; 1/1000 - &lt; 1/100)</p><p>Rare (&ge; 1/10000 - &lt; 1/1000)</p><p>Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:736px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:237px"><p><strong>Rare</strong></p></td><td style="vertical-align:top; width:58px"><p><strong>Not Known a</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Genital fungal infection</p></td><td style="vertical-align:top; width:237px"><p>Pseudo- membranous colitisb</p></td><td style="vertical-align:top; width:58px"><p>Superinfection</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Eosinophilia Leucopenia Thrombocytopenia</p></td><td style="vertical-align:top"><p>Granulocytopenia Anaemia Coagulopathy</p></td><td style="vertical-align:top; width:237px"><p>&nbsp;</p></td><td style="vertical-align:top; width:58px"><p>Haemolytic anaemiab Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Immune</p><p>system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:237px"><p>&nbsp;</p></td><td style="vertical-align:top; width:58px"><p>Anaphylactic shock Anaphylactic reaction Anaphylactoid reaction Hypersensitivityb Jarisch- Herxheimer reaction</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous</p><p>system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache Dizziness</p></td><td style="vertical-align:top; width:237px"><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;Encephalopathy</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table>&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:237px"><p>&nbsp;</p></td><td style="vertical-align:top; width:58px"><p>Vertigo</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoeab Loose stools</p></td><td style="vertical-align:top"><p>Nausea Vomiting</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitisb Stomatitis Glossitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gall bladder precipitationb Kernicterus</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Stevens Johnson Syndromeb Toxic epidermal necrolysisb Erythema multiforme Acute generalised exanthematous pustulosis, drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria Glycosuria</p></td><td style="vertical-align:top"><p>Oliguria Renal precipitation (reversible)</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Phlebitis Injection site pain Pyrexia</p></td><td style="vertical-align:top"><p>Oedema Chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Coombs test false positiveb Galactosaemia test false positive b</p><p>Non enzymatic methods for glucose determination false&nbsp;positive b</p></td></tr></tbody></table><p>&nbsp;</p><p><br />Based on post-marketing reports. Since these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore</p><p>categorised as not known.</p><p>b&nbsp;&nbsp; See section 4.4</p><p><sup>c</sup> Usually reversible upon discontinuation of ceftriaxone</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>I</em><em>nfections and infestations</em></p><p>Reports of diarrhoea following the use of ceftriaxone may be associated with <em>Clostridium difficile</em>. Appropriate fluid and electrolyte management should be instituted (see section 4.4).</p><p>&nbsp;</p><p><em>C</em><em>eftriaxone-calcium salt precipitation</em></p><p>Rarely, severe, and in some cases, fatal, adverse reactions have been reported in pre-term and full-term neonates (aged &lt; 28 days) who had been treated with intravenous ceftriaxone and calcium.</p><p>Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The</p><p>high risk of precipitation in neonates is a result of their low blood volume and the longer half-life of ceftriaxone compared with adults (see sections 4.3, 4.4, and 5.2).</p><p>&nbsp;</p><p>Cases of ceftriaxone precipitation in the urinary tract have been reported, mostly in children treated with high doses (e.g. &ge; 80 mg/kg/day) or total doses exceeding 10 grams) and who have other risk factors (e.g. dehydration, confinement to bed). This event may be asymptomatic or symptomatic, and may lead to ureteric obstruction and postrenal acute renal failure, but is usually reversible upon discontinuation of ceftriaxone (see section 4.4).</p><p>&nbsp;</p><p>Precipitation of ceftriaxone calcium salt in the gallbladder has been observed, primarily in patients treated with doses higher than the recommended standard dose. In children, prospective studies have shown a variable incidence of precipitation with intravenous application - above 30 % in some studies. The incidence appears to be lower with slow infusion (20 - 30 minutes). This effect is usually asymptomatic, but the precipitations have been accompanied by clinical symptoms such as pain, nausea and vomiting in rare cases. Symptomatic treatment is recommended in these cases.</p><p>Precipitation is usually reversible upon discontinuation of ceftriaxone (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;&nbsp; To reports any side effect(s):</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In overdose, the symptoms of nausea, vomiting and diarrhoea can occur<em>.</em><strong><em> </em></strong>Ceftriaxone concentrations cannot be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdose should be symptomatic.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antibacterials for systemic use, Third-generation cephalosporins, ATC</p><p>code: J01DD04.</p><p>&nbsp;</p><p><u>M</u><u>ode of action</u></p><p>&nbsp;</p><p>Ceftriaxone inhibits bacterial cell wall synthesis following attachment to penicillin binding proteins (PBPs). This results in the interruption of cell wall (peptidoglycan) biosynthesis, which leads to bacterial cell lysis and death.</p><p>&nbsp;</p><p><u>R</u><u>esistance</u></p><p>&nbsp;</p><p>Bacterial resistance to ceftriaxone may be due to one or more of the following mechanisms:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hydrolysis by beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), carbapenemases and Amp C enzymes that may be induced or stably derepressed in certain aerobic Gram-negative bacterial species.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced affinity of penicillin-binding proteins for ceftriaxone.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; outer membrane impermeability in Gram-negative organisms.</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial efflux pumps. <u>Susceptibility testing breakpoints</u></p><p>Minimum inhibitory concentration (MIC) breakpoints established by the European Committee on</p><p>Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Pathogen</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Dilution Test (MIC, mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterobacteriaceae</em></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus </em>spp.</p></td><td style="vertical-align:top"><p>a.</p></td><td style="vertical-align:top"><p>a.</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus </em>spp.</p><p><em>(</em>Groups A, B, C and G)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>b.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>b.</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td style="vertical-align:top"><p>&le; 0.5c.</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr><tr><td style="vertical-align:top"><p>Viridans group <em>Streptococci</em></p></td><td style="vertical-align:top"><p>&le;0.5</p></td><td style="vertical-align:top"><p>&gt;0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td style="vertical-align:top"><p>&le; 0.12c.</p></td><td style="vertical-align:top"><p>&gt; 0.12</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td style="vertical-align:top"><p>&le; 1</p></td><td style="vertical-align:top"><p>&gt; 2</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0" style="width:340px"><tbody><tr><td style="vertical-align:top; width:179px"><p><em>Neisseria gonorrhoeae</em></p></td><td style="vertical-align:top; width:83px"><p>&le; 0.12</p></td><td style="vertical-align:top; width:77px"><p>&gt; 0.12</p></td></tr><tr><td style="vertical-align:top; width:179px"><p><em>Neisseria meningitidis</em></p></td><td style="vertical-align:top; width:83px"><p>&le; 0.12 c.</p></td><td style="vertical-align:top; width:77px"><p>&gt; 0.12</p></td></tr><tr><td style="vertical-align:top; width:179px"><p>Non-species related</p></td><td style="vertical-align:top; width:83px"><p>&le; 1d.</p></td><td style="vertical-align:top; width:77px"><p>&gt; 2</p></td></tr></tbody></table><p>a.&nbsp;&nbsp;&nbsp; Susceptibility inferred from cefoxitin susceptibility.</p><p>b.&nbsp;&nbsp; Susceptibility inferred from penicillin susceptibility.</p><p>c.&nbsp;&nbsp;&nbsp; Isolates with a ceftriaxone MIC above the susceptible breakpoint are rare and, if found, should be re-tested and, if confirmed, should be sent to a reference laboratory.</p><p>d.&nbsp;&nbsp; Breakpoints apply to a daily intravenous dose of 1 g x 1 and a high dose of at least 2 g x 1.</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p>&nbsp;</p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of ceftriaxone in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Gram-positive aerobes</u></p><p>&nbsp;</p><p><em>Staphylococcus aureus </em>(methicillin-susceptible)&pound; Staphylococci coagulase-negative (methicillin- susceptible)&pound; <em>Streptococcus pyogenes </em>(Group A)</p><p><em>Streptococcus agalactiae </em>(Group B)</p><p><em>Streptococcus pneumoniae</em></p><p>Viridans Group <em>Streptococci</em></p><p>&nbsp;</p><p><u>Gram-negative aerobes</u></p><p>&nbsp;</p><p><em>Borrelia burgdorferi Haemophilus influenzae Haemophilus parainfluenzae Moraxella catarrhalis Neisseria gonorrhoea Neisseria meningitidis Proteus mirabilis Providencia </em>spp</p><p><em>Treponema pallidum</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Gram-positive aerobes</u></p><p>&nbsp;</p><p><em>Staphylococcus epidermidis+ Staphylococcus haemolyticus+ Staphylococcus hominis+</em></p><p>Gram-negative aerobes</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli% Klebsiella pneumoniae% Klebsiella oxytoca% Morganella morganii Proteus vulgaris Serratia marcescens</em></p><p><u>Anaerobes</u></p><p>&nbsp;</p><p><em>Bacteroides </em>spp<em>. Fusobacterium </em>spp. <em>Peptostreptococcus </em>spp. <em>Clostridium perfringens</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p><p><u>Gram-positive aerobes</u></p><p>&nbsp;</p><p><em>Enterococcus </em>spp.</p><p><em>Listeria monocytogenes</em></p><p>&nbsp;</p><p><u>Gram-negative aerobes</u></p><p><em>Acinetobacter baumannii Pseudomonas aeruginosa Stenotrophomonas maltophilia</em></p><p>&nbsp;</p><p><u>Anaerobes</u></p><p>&nbsp;</p><p><em>Clostridium difficile</em></p><p>&nbsp;</p><p><u>Others:</u></p><p><em>Chlamydia </em>spp. <em>Chlamydophila </em>spp. <em>Mycoplasma </em>spp. <em>Legionella </em>spp. <em>Ureaplasma urealyticum</em></p></td></tr></tbody></table><p>&pound;&nbsp;&nbsp; All methicillin-resistant staphylococci are resistant to ceftriaxone.</p><p>+&nbsp;&nbsp; Resistance rates &gt;50% in at least one region</p><p>%&nbsp;&nbsp;&nbsp; ESBL producing strains are always resistant</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p><em><u>Intramuscular administration</u></em></p><p>Following intramuscular injection, mean peak plasma ceftriaxone levels are approximately half those observed after intravenous administration of an equivalent dose. The maximum plasma concentration after a single intramuscular dose of 1 g is about 81 mg/l and is reached in 2 - 3 hours after administration.</p><p>The area under the plasma concentration-time curve after intramuscular administration is equivalent to that after intravenous administration of an equivalent dose.</p><p>&nbsp;</p><p><em><u>Intravenous administration</u></em></p><p>After intravenous bolus administration of ceftriaxone 500 mg and 1 g, mean peak plasma ceftriaxone levels are approximately 120 and 200 mg/l respectively. After intravenous infusion of ceftriaxone</p><p>&nbsp;</p><p>500 mg, 1 g and 2 g, the plasma ceftriaxone levels are approximately 80, 150 and 250 mg/l respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The volume of distribution of ceftriaxone is 7 &ndash; 12 l. Concentrations well above the minimal inhibitory concentrations of most relevant pathogens are detectable in tissue including lung, heart, biliary tract/liver, tonsil, middle ear and nasal mucosa, bone, and in cerebrospinal, pleural, prostatic and synovial fluids. An 8 - 15 % increase in mean peak plasma concentration (Cmax ) is seen on repeated administration; steady state is reached in most cases within 48 - 72 hours depending on the route of administration.</p><p>&nbsp;</p><p><em><u>Penetration into particular tissues</u></em></p><p><em>&nbsp;</em></p><p>Ceftriaxone penetrates the meninges. Penetration is greatest when the meninges are inflamed. Mean peak ceftriaxone concentrations in CSF in patients with bacterial meningitis are reported to be up to 25 % of plasma levels compared to 2 % of plasma levels in patients with uninflamed meninges. Peak ceftriaxone concentrations in CSF are reached approximately 4-6 hours after intravenous injection. Ceftriaxone crosses the placental barrier and is excreted in the breast milk at low concentrations (see section 4.6).</p><p>&nbsp;</p><p><em><u>Protein binding</u></em></p><p><em>&nbsp;</em></p><p>Ceftriaxone is reversibly bound to albumin. Plasma protein binding is about 95 % at plasma concentrations below 100 mg/l. Binding is saturable and the bound portion decreases with rising concentration (up to 85 % at a plasma concentration of 300 mg/l).</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Ceftriaxone is not metabolised systemically; but is converted to inactive metabolites by the gut flora. <u>Elimination</u></p><p>Plasma clearance of total ceftriaxone (bound and unbound) is 10 - 22 ml/min. Renal clearance is 5 - 12 ml/min. 50 - 60 % of ceftriaxone is excreted unchanged in the urine, primarily by glomerular filtration, while 40 - 50 % is excreted unchanged in the bile. The elimination half-life of total ceftriaxone in adults is about 8 hours.</p><p>&nbsp;</p><p><em><u>Patients with renal or hepatic impairment</u></em></p><p><em>&nbsp;</em></p><p>In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only minimally altered with the half-life slightly increased (less than two fold), even in patients with severely impaired renal function.</p><p>&nbsp;</p><p>The relatively modest increase in half-life in renal impairment is explained by a compensatory increase in non-renal clearance, resulting from a decrease in protein binding and corresponding increase in non-renal clearance of total ceftriaxone.</p><p>&nbsp;</p><p>In patients with hepatic impairment, the elimination half-life of ceftriaxone is not increased, due to a compensatory increase in renal clearance. This is also due to an increase in plasma free fraction of ceftriaxone contributing to the observed paradoxical increase in total drug clearance, with an increase in volume of distribution paralleling that of total clearance.</p><p>&nbsp;</p><p><em><u>Older people</u></em></p><p><em>&nbsp;</em></p><p>In older people aged over 75 years the average elimination half-life is usually two to three times that of young adults.</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p><em>&nbsp;</em></p><p>The half-life of ceftriaxone is prolonged in neonates. From birth to 14 days of age, the levels of free ceftriaxone may be further increased by factors such as reduced glomerular filtration and altered protein binding. During childhood, the half-life is lower than in neonates or adults.</p><p>The plasma clearance and volume of distribution of total ceftriaxone are greater in neonates, infants and children than in adults.</p><p>&nbsp;</p><p><u>Linearity/non-linearity</u></p><p>&nbsp;</p><p>The pharmacokinetics of ceftriaxone are non-linear and all basic pharmacokinetic parameters, except the elimination half-life, are dose dependent if based on total drug concentrations, increasing less than proportionally with dose. Non-linearity is due to saturation of plasma protein binding and is therefore observed for total plasma ceftriaxone but not for free (unbound) ceftriaxone.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u></p><p>&nbsp;</p><p>As with other beta-lactams, the pharmacokinetic-pharmacodynamic index demonstrating the best correlation with <em>in vivo </em>efficacy is the percentage of the dosing interval that the unbound concentration remains above the minimum inhibitory concentration (MIC) of ceftriaxone for individual target species (i.e. %T &gt; MIC).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is evidence from animal studies that high doses of ceftriaxone calcium salt led to formation of concrements and precipitates in the gallbladder of dogs and monkeys, which proved to be reversible.</p><p>Animal studies produced no evidence of toxicity to reproduction and genotoxicity. Carcinogenicity studies on ceftriaxone were not conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Powder:</p><p>None</p><p>&nbsp;</p><p>Solvent i.m.:</p><p>lidocaine hydrochloride</p><p>water for injections</p><p>sodium hydrogen carbonate</p><p>&nbsp;</p><p>Solvent i.v.:</p><p>water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on literature reports, ceftriaxone is not compatible with amsacrine, vancomycin, fluconazole, aminoglycosides and labetalol.</p><p>&nbsp;</p><p>Solutions containing ceftriaxone should not be mixed with or added to other agents except those mentioned in section 6.6. In particular diluents containing calcium (e.g. Ringer&rsquo;s solution or Hartmann&rsquo;s solution), should not be used to reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a precipitate can form. Ceftriaxone must not be mixed or administered simultaneously with calcium-containing solutions (see sections 4.2, 4.3, 4.4, and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder: 3 years.
Reconstituted solution: For immediate use.

Reconstituted solution: 
Chemical and physical stability has been demonstrated for 24 hours at 2 – 8 °C.

From a microbiological point of view, the reconstituted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would not be longer than 24 hours at 2 to 8 °C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original carton in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Megion 0.5 g powder and solvent for solution for injection</p><p>Powder vial: Colourless 15 ml type III glass vial with halogenated butyl rubber stopper covered with aluminium caps and plastic flip-off caps.</p><p>Solvent ampoule: Colourless5 ml type I &nbsp;glass ampoule</p><p>&nbsp;</p><p>Pack sizes:</p><p>1 vial + 1 ampoule</p><p>&nbsp;</p><p>Megion 1 g powder and solvent for solution for injection</p><p>Powder vial: Colourless 15 ml type III glass vials closed with halogenated butyl rubber stopper covered with aluminium caps and plastic flip-offs</p><p>Solvent ampoule: Colourless5 ml clear type I glass ampoule</p><p>&nbsp;</p><p>Pack sizes:</p><p>1 vial + 1 ampoule</p><p>&nbsp;</p><p>Megion 1 g powder and solvent for solution for injection<em> </em>/infusion</p><p>Powder vial: Colourless 15 ml type III glass vials closed with halogenated butyl rubber stopper covered with aluminium caps and plastic flip-off caps</p><p>Solvent ampoule: Colourless LDPE ampoule.</p><p>&nbsp;</p><p>Pack size:</p><p>1 vial + 1 ampoule</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftriaxone should not be mixed in the same syringe with any drug other than 1 % lidocaine hydrochloride solution (for intramuscular injection only).</p><p>&nbsp;</p><p>Do not use diluents containing calcium, such as Ringer&rsquo;s solution or Hartmann&rsquo;s solution, to reconstitute Megion. Particulate formation can result.</p><p><em>&nbsp;</em></p><p><em>Intramuscular injection:</em></p><p>Megion 1 g powder &nbsp;should be dissolved in 3.5 ml of 1 % lidocaine hydrochloride solution.</p><p>The solution should be administered by deep intramuscular injection.</p><p>Dosages greater than 1 g should be divided and injected at more than one site.</p><p>Solutions of lidocaine should not be administered intravenously.</p><p><em>Intravenous injection:</em></p><p>Megion 1 g powder &nbsp;should be dissolved in 10 ml of water for injections.</p><p>The injection should be administered over at least 5 minutes, directly into the vein or via the tubing of an intravenous infusion.</p><p><em>&nbsp;</em></p><p><em>Intravenous infusion:</em></p><p>Megion 1 g powder &nbsp;should be dissolved in 20 to 40 ml of one of the following calcium-free infusion solutions:</p><p>Sodium chloride 0.9%, sodium chloride 0.45% and glucose 2.5%, glucose 5 % or 10%, dextran 6% in glucose 5%, hydroxyethyl starch 6-10% infusions.</p><p>See also the information included in section 6.2.</p><p>The infusion should be administered over at least 30 minutes.</p><p>&nbsp;</p><p>When reconstituted for intramuscular or intravenous injection, the white to yellowish-orange crystalline powder gives a pale yellow to amber solution.</p><p>Reconstituted solutions should be inspected visually. Only clear solutions free of visible particles should be used. The reconstituted product is for single use only.</p><p>&nbsp;</p><p>&nbsp;</p><p>Disposal:</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                            Sandoz GmbH, Kundl, Austria
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>